The Predictors of Local Recurrence After Radical Cystectomy in Patients with Invasive Bladder Cancer

	Tweet

Although radical cystectomy has been considered the gold standard curative treatment for invasive bladder cancer, around one third of the patients relapse and die of the disease after surgery. The main reason for cancer death in patients treated with radical cystectomy has been associated with the development of distant metastasis. Meanwhile, long-term survival after local recurrence is also extremely rare. Thus, local recurrence is thought to be as important as distant metastasis for disease specific survival. However, few studies have discussed the clinical course and natural history of local recurrence in patients with bladder cancer. The association between local recurrence and distant metastasis has also not been fully evaluated.

In this study, we retrospectively reviewed patients who underwent radical cystectomy for invasive bladder cancer in order to examine the association between local recurrence and distant metastasis or disease specific survival and identify independent factor predictors for local recurrence.

We identified a study population of 146 consecutive patients treated surgically for invasive bladder cancer at our institution between 1987 and 2003. We clarified the relationship among local recurrence, distant metastasis and disease specific survival and identified significant predictors for local recurrence.

Local recurrence developed in 26 (17.8%) of the 146 patients at a median of 10 months (range, 1 to 73 months) after cystectomy. Local recurrence was independently associated with distant metastasis in addition to the number of retrieved lymph nodes. The 2- and 5-year metastasis free rates were 86.7% and 76.5% in patients without local recurrence and 26.5% and 0% in those with local recurrence (P <0.001). The presence or absence of local recurrence and tumor grade were independent predictors of disease specific survival. The 2- and 5-year disease specific survival rates were 93.5% and 88.3% in patients without local recurrence and 55.1% and 35.4% in those with local recurrence (P <0.001). The presence of concomitant adenocarcinoma component, pathological nodal involvement, and the number of retrieved lymph nodes were independent predictors of local recurrence.

Our study revealed that local recurrence was independently associated with distant metastasis and disease specific survival. The predictive factors described above might help us select a subgroup of patients who would benefit from optimal local control, subsequently reducing distant metastasis and improving disease specific survival. There are some strategies for local control such as aggressive surgical extirpation of tissue adjacent to bladder, extended lymph node dissection and adjuvant therapy that includes a new chemotherapeutic regimen or novel molecular targeting therapy in the future. Based on our results, extensive lymph node dissection would be of benefit to reduce local recurrence.

Written by
Hiroki Ide, MD, Eiji Kikuchi, MD, Akira Miyajima, MD, Ken Nakagawa, MD, Takashi Ohigashi, MD, Jun Nakashima, MD, and Mototsugu Oya, MD, as part of Beyond the Abstract on UroToday.com.

Source: UroToday

RELATED STORIES:
Estrogen use tied to bladder control problems   Protein Key to Bladder Cancer Spread, Potential Drug Target   Genetic analysis may predict risk of invasive bladder cancer   Survival and Response to Therapy of Non-Invasive Bladder Cancer Patients   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Not enough evidence for bladder cancer screening   Early menopause related to bladder cancer risk   Consumption of Cultured Milk Products May Reduce Bladder Cancer Risk   Gene test shows which bladder cancer patients may have cancer spread   Bladder cancer: Need for a standardized protocol of management   Brochure Helps Patients Understand Treatments for Bladder Cancer   Meat, Especially If It’s Well Done, May Increase Risk of Bladder Cancer   Selenium May Prevent High Risk-Bladder Cancer   UT Southwestern researchers investigate high-risk populations for bladder-cancer screenings   AUA releases new guidelines on non-muscle invasive bladder cancer   Robotic Surgery Extends Benefits to Bladder Cancer Patients   Measurement of Urinary Protein Can Help Detect Recurrent Bladder Cancer   Radiation does not improve survival for rare, invasive bladder cancer   Delaying bladder cancer surgery increases mortality   MDCT Shows Potential for Detecting Bladder Cancer Without Surgery or Contrast   Patients unaware of link between smoking and bladder cancer   Survivors of Childhood Cancers Treated with Cyclophosphamide More Likely to Develop Bladder Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]